Abstract
Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Current Pharmaceutical Biotechnology
Title:Brain Drug Delivery Systems for Neurodegenerative Disorders
Volume: 13 Issue: 12
Author(s): E. Garbayo, E. Ansorena and M.J. Blanco-Prieto
Affiliation:
Keywords: Drug delivery systems, neurodegenerative disorders, stereotactic surgery, blood brain barrier, Alzheimer’s disease (AD), pharmacological and therapeutic properties, conventional drugs, neurodegenerative disorders, polymeric micro, lipidic nanoparticles, pegylated liposomes, Parkinson’s disease (PD), microemulsion, drug delivery
Abstract: Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinson’s, Alzheimer’s and Hungtinton’s disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.
Export Options
About this article
Cite this article as:
Garbayo E., Ansorena E. and Blanco-Prieto M.J., Brain Drug Delivery Systems for Neurodegenerative Disorders, Current Pharmaceutical Biotechnology 2012; 13 (12) . https://dx.doi.org/10.2174/138920112803341761
DOI https://dx.doi.org/10.2174/138920112803341761 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA in Implant Dentistry: From Basic Science to Clinical Application
MicroRNA Histone Deacetylation and Motor Neuron Degeneration
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Auditory Processing Disorder (Guest Editors: Vasiliki Maria Iliadou)]
Current Pediatric Reviews Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer’s Disease Patients
Current Alzheimer Research Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Sphingolipids as Targets for Microbial Infections
Mini-Reviews in Medicinal Chemistry The Application of Proteomics in Neurology
Current Proteomics Addressing Alzheimer’s Disease and Cognitive Loss through Autophagy
Current Neurovascular Research Editorial (Hot Topic: Targeting Histone Acetylation for Neuroprotection)
Current Pharmaceutical Design Creatine and the Liver: Metabolism and Possible Interactions
Mini-Reviews in Medicinal Chemistry Micro-RNA in Disease and Gene Therapy
Current Drug Discovery Technologies Dissecting the Biological Effects of Isoflurane through the Mechanistic Target of Rapamycin (mTOR) and microRNAs (miRNAs)
Current Neurovascular Research Production of Retroviral Vectors: Review
Current Gene Therapy Current Challenges to Overcome in the Management of Type 2 Diabetes Mellitus and Associated Neurological Disorders
CNS & Neurological Disorders - Drug Targets Recent Patents Relating to Diagnostic Advances in Age Related Macular Degeneration (AMD)
Recent Patents on DNA & Gene Sequences Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging